vs
Side-by-side financial comparison of FVCBankcorp, Inc. (FVCB) and LIFECORE BIOMEDICAL, INC. \DE\ (LFCR). Click either name above to swap in a different company.
LIFECORE BIOMEDICAL, INC. \DE\ is the larger business by last-quarter revenue ($31.1M vs $16.9M, roughly 1.8× FVCBankcorp, Inc.). On growth, FVCBankcorp, Inc. posted the faster year-over-year revenue change (4377.5% vs -4.5%). FVCBankcorp, Inc. produced more free cash flow last quarter ($23.8M vs $25.0K). Over the past eight quarters, FVCBankcorp, Inc.'s revenue compounded faster (586.6% CAGR vs -0.1%).
FVCBankcorp, Inc. is a Virginia-based U.S. bank holding company operating FVCbank, a community-focused financial institution. It provides a full range of personal and commercial banking products including deposit accounts, business and personal loans, mortgage services, and wealth management solutions, serving SMEs, professionals and individual consumers across the Mid-Atlantic region.
LIFECORE BIOMEDICAL, INC. is a biomedical firm focused on developing and manufacturing high-quality hyaluronic acid-based biomaterials. It operates three core segments: medical application products, pharmaceutical solutions, and personal care ingredients, with main markets spanning North America, Europe and the Asia-Pacific, supplying to leading medical device, pharmaceutical and cosmetic brand partners.
FVCB vs LFCR — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $16.9M | $31.1M |
| Net Profit | — | $-10.0M |
| Gross Margin | — | 25.0% |
| Operating Margin | 43.7% | -9.9% |
| Net Margin | — | -32.1% |
| Revenue YoY | 4377.5% | -4.5% |
| Net Profit YoY | — | -52.0% |
| EPS (diluted) | $0.31 | $-0.29 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.9M | — | ||
| Q3 25 | $416.0K | $31.1M | ||
| Q2 25 | $15.8M | — | ||
| Q1 25 | $382.0K | $35.2M | ||
| Q4 24 | $378.0K | $32.6M | ||
| Q3 24 | $412.0K | $24.7M | ||
| Q2 24 | $415.0K | — | ||
| Q1 24 | $359.0K | $35.7M |
| Q4 25 | — | — | ||
| Q3 25 | $5.6M | $-10.0M | ||
| Q2 25 | $5.7M | — | ||
| Q1 25 | $5.2M | $-14.8M | ||
| Q4 24 | — | $-6.6M | ||
| Q3 24 | $4.7M | $-16.2M | ||
| Q2 24 | $4.2M | — | ||
| Q1 24 | $1.3M | $15.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | 25.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 28.0% | ||
| Q4 24 | — | 34.0% | ||
| Q3 24 | — | 21.8% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 33.3% |
| Q4 25 | 43.7% | — | ||
| Q3 25 | — | -9.9% | ||
| Q2 25 | 45.9% | — | ||
| Q1 25 | — | -25.7% | ||
| Q4 24 | — | -6.0% | ||
| Q3 24 | — | -46.9% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -2.5% |
| Q4 25 | — | — | ||
| Q3 25 | 1341.1% | -32.1% | ||
| Q2 25 | 36.0% | — | ||
| Q1 25 | 1352.1% | -42.0% | ||
| Q4 24 | — | -20.2% | ||
| Q3 24 | 1133.3% | -65.7% | ||
| Q2 24 | 1001.2% | — | ||
| Q1 24 | 373.3% | 43.8% |
| Q4 25 | $0.31 | — | ||
| Q3 25 | $0.31 | $-0.29 | ||
| Q2 25 | $0.31 | — | ||
| Q1 25 | $0.28 | $-0.47 | ||
| Q4 24 | $0.27 | $-0.25 | ||
| Q3 24 | $0.25 | $-0.53 | ||
| Q2 24 | $0.23 | — | ||
| Q1 24 | $0.07 | $0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $18.9M |
| Total DebtLower is stronger | — | $136.0M |
| Stockholders' EquityBook value | $253.6M | $-10.5M |
| Total Assets | $2.3B | $235.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | $18.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $5.4M | ||
| Q4 24 | — | $9.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $136.0M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $124.9M | ||
| Q4 24 | — | $111.3M | ||
| Q3 24 | — | $106.3M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $97.1M |
| Q4 25 | $253.6M | — | ||
| Q3 25 | $249.8M | $-10.5M | ||
| Q2 25 | $243.2M | — | ||
| Q1 25 | $242.3M | $2.2M | ||
| Q4 24 | $235.4M | $15.4M | ||
| Q3 24 | $230.8M | $-3.9M | ||
| Q2 24 | $226.5M | — | ||
| Q1 24 | $220.7M | $17.7M |
| Q4 25 | $2.3B | — | ||
| Q3 25 | $2.3B | $235.2M | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | $237.7M | ||
| Q4 24 | $2.2B | $255.4M | ||
| Q3 24 | $2.3B | $246.8M | ||
| Q2 24 | $2.3B | — | ||
| Q1 24 | $2.2B | $246.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 56.05× | ||
| Q4 24 | — | 7.20× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 5.49× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $23.9M | $1.8M |
| Free Cash FlowOCF − Capex | $23.8M | $25.0K |
| FCF MarginFCF / Revenue | 140.7% | 0.1% |
| Capex IntensityCapex / Revenue | 0.3% | 5.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $40.0M | $-16.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $23.9M | — | ||
| Q3 25 | $7.6M | $1.8M | ||
| Q2 25 | $3.3M | — | ||
| Q1 25 | $5.4M | $1.2M | ||
| Q4 24 | $18.2M | $-6.1M | ||
| Q3 24 | $4.7M | $-613.0K | ||
| Q2 24 | $1.6M | — | ||
| Q1 24 | $7.2M | $-1.4M |
| Q4 25 | $23.8M | — | ||
| Q3 25 | $7.6M | $25.0K | ||
| Q2 25 | $3.3M | — | ||
| Q1 25 | $5.4M | $-4.3M | ||
| Q4 24 | $18.1M | $-8.6M | ||
| Q3 24 | $4.6M | $-4.0M | ||
| Q2 24 | $1.5M | — | ||
| Q1 24 | $7.1M | $-7.8M |
| Q4 25 | 140.7% | — | ||
| Q3 25 | 1818.0% | 0.1% | ||
| Q2 25 | 20.8% | — | ||
| Q1 25 | 1413.6% | -12.1% | ||
| Q4 24 | 4786.0% | -26.3% | ||
| Q3 24 | 1121.8% | -16.3% | ||
| Q2 24 | 361.2% | — | ||
| Q1 24 | 1988.3% | -21.8% |
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.2% | 5.6% | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 4.2% | 15.5% | ||
| Q4 24 | 37.3% | 7.5% | ||
| Q3 24 | 14.1% | 13.9% | ||
| Q2 24 | 12.8% | — | ||
| Q1 24 | 3.9% | 17.8% |
| Q4 25 | — | — | ||
| Q3 25 | 1.36× | — | ||
| Q2 25 | 0.58× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.00× | — | ||
| Q2 24 | 0.37× | — | ||
| Q1 24 | 5.34× | -0.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FVCB
Segment breakdown not available.
LFCR
| Transferred At Point In Time | $26.6M | 85% |
| Transferred Over Time | $4.5M | 15% |
